Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial
Charles J. Fisher, Michael A. Catalano(Children's Hospital of Philadelphia), Gus J. Slotman(Apple (Israel)), John P. Pribble(Apple (Israel)), Duane C. Bloedow(Emmanuel College - Massachusetts), George Emmanuel(Emmanuel College - Massachusetts), David P. Ng(Emmanuel College - Massachusetts), Roger C. Bone(University of Arkansas for Medical Sciences), Steven M. Opal(Brown University)
Cited by 490
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k